Skip to content
2000
image of Cinnoline Derivatives in Breast Cancer Therapy: A Comprehensive Review of Their Therapeutic Potential

Abstract

Breast cancer remains a major global health concern, contributing substantially to cancer-related morbidity and mortality among women. Despite advances in treatment, challenges such as drug resistance, systemic toxicity, and disease recurrence highlight the need for novel therapeutic agents. Cinnoline derivatives have emerged as promising anticancer compounds due to their diverse pharmacological properties. These heterocyclic molecules exert potent antiproliferative effects through multiple mechanisms, including induction of apoptosis, cell cycle arrest, and inhibition of oncogenic signaling pathways such as PI3K/Akt/mTOR and MAPK.

Moreover, cinnoline derivatives show potential in overcoming drug resistance by modulating efflux transporters and targeting cancer stem cells. Their pharmacokinetic profile—including absorption, distribution, metabolism, and excretion (ADME)—critically influences clinical viability. Challenges such as poor solubility, rapid metabolism, and inefficient absorption limit oral bioavailability, while lipophilicity and CYP450-mediated metabolism affect drug half-life, clearance, and overall therapeutic performance.

Recent advancements in drug delivery strategies have improved the bioavailability and therapeutic index of cinnoline derivatives. Nanocarrier-based systems, including liposomes and polymeric nanoparticles, enable targeted delivery, minimizing systemic toxicity while enhancing efficacy. Additionally, cinnoline derivatives have demonstrated synergistic effects when combined with conventional chemotherapeutics, immunotherapies, and hormone-based treatments, providing promising avenues for combination therapy.

Nevertheless, optimizing pharmacokinetics, reducing off-target toxicity, and ensuring clinical translation remain significant challenges. Future research should focus on structural modifications, personalized medicine approaches, and rigorous preclinical and clinical evaluations to validate safety and efficacy. Overall, cinnoline derivatives hold substantial potential to revolutionize breast cancer therapy, offering more precise, effective, and well-tolerated treatment options.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdth/10.2174/0115748855421240251126060327
2026-03-27
2026-04-17

  • From This Site

    /content/journals/cdth/10.2174/0115748855421240251126060327
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Trapani D. Ginsburg O. Fadelu T. Global challenges and policy solutions in breast cancer control. Cancer Treat. Rev. 2022 104 102339 10.1016/j.ctrv.2022.102339 35074727
    [Google Scholar]
  2. Sharma M. Bakshi A.K. Mittapelly N. Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. J. Control. Release 2022 346 43 70 10.1016/j.jconrel.2022.04.007 35405165
    [Google Scholar]
  3. Kunjiappan S. Panneerselvam T. Govindaraj S. Design, in silico modelling, and functionality theory of novel folate receptor targeted rutin encapsulated folic acid conjugated keratin nanoparticles for effective cancer treatment. Anticancer. Agents Med. Chem. 2020 19 16 1966 1982 10.2174/1871520619666190702145609 31267878
    [Google Scholar]
  4. Kunjiappan S. Panneerselvam T. Somasundaram B. Arunachalam S. Sankaranarayanan M. Parasuraman P. Preparation of liposomes encapsulated Epirubicin-gold nanoparticles for Tumor specific delivery and release. Biomed. Phys. Eng. Express 2018 4 4 045027 10.1088/2057‑1976/aac9ec
    [Google Scholar]
  5. Bharathiraja P. Yadav P. Sajid A. Ambudkar S.V. Prasad N.R. Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer. Drug Resist. Updat. 2023 71 101004 10.1016/j.drup.2023.101004 37660590
    [Google Scholar]
  6. Alismail H. Review: Merging from traditional to potential novel breast cancer biomarkers. J. King Saud Univ. Sci. 2024 36 11 103551 10.1016/j.jksus.2024.103551
    [Google Scholar]
  7. Al Kawas H. Saaid I. Jank P. How VEGF-A and its splice variants affect breast cancer development – clinical implications. Cell. Oncol. 2022 45 2 227 239 10.1007/s13402‑022‑00665‑w 35303290
    [Google Scholar]
  8. Brogowska K.K. Zajkowska M. Mroczko B. Vascular endothelial growth factor ligands and receptors in breast cancer. J. Clin. Med. 2023 12 6 2412 10.3390/jcm12062412 36983412
    [Google Scholar]
  9. Madu C.O. Wang S. Madu C.O. Lu Y. Angiogenesis in breast cancer progression, diagnosis, and treatment. J. Cancer 2020 11 15 4474 4494 10.7150/jca.44313 32489466
    [Google Scholar]
  10. Clément S. Winum J-Y. Photodynamic therapy alone or in combination to counteract bacterial infections. Expert Opin. Ther. Pat. 2024 34 6 401 414 10.1080/13543776.2024.2327308
    [Google Scholar]
  11. Kunjiappan S. Panneerselvam T. Pavadai P. Fabrication of folic acid-conjugated pyrimidine-2(5H)-thione-encapsulated curdlan gum-PEGamine nanoparticles for folate receptor targeting breast cancer cells. Int. J. Biol. Macromol. 2024 277 Pt 3 134406 10.1016/j.ijbiomac.2024.134406 39097067
    [Google Scholar]
  12. Manoharan A. Theivendren P. Sharma M. Kunjiappan S. Govindaraj S. Pavadai P. Design, molecular modelling, synthesis, characterization studies of novel N-(7-(substituted benzylidene)-4-phenyl-4, 5, 6, 7-tetrahydro-3H-cyclopenta [d] pyrimidin-2-yl)-1-(substituted phenyl) methanimine against breast cancer. J. Indian Chem. Soc. 2025 22 3 561 573
    [Google Scholar]
  13. Panneerselvam T. Kunjiappan S. Govindaraj S. Graph Theoretical analysis, in silico modeling and molecular dynamic studies of (5-((2-chloropyridin-4-yl)oxy)-3-phenyl-1H-pyrazol-1-yl)-2-(4-substituted phenyl)-N,N-dimethylethen-1-amine derivatives for the treatment of breast cancer. Anticancer. Agents Med. Chem. 2022 23 10.2174/1871520623666221205140328 36475343
    [Google Scholar]
  14. Sroor F.M. Othman A.M. Aboelenin M.M. Mahrous K.F. Anticancer and antimicrobial activities of new thiazolyl-urea derivatives: Gene expression, DNA damage, DNA fragmentation and SAR studies. Med. Chem. Res. 2022 31 3 400 415 10.1007/s00044‑022‑02849‑3
    [Google Scholar]
  15. Kumar P.D. Kumar P.V. Anneer Selvam T. Rao K.S. Prolonged drug delivery system of PEGylated PAMAM dendrimers with a anti-HIV drug. Res Pharm 2013 3 2 8 17
    [Google Scholar]
  16. Prakash C. Raja S.P.T. Saravanan G. Karthick V. Kumar P.D. Synthesis and anti-microbial activities of some novel schiff bases of 5-substituted isatin derivatives. Rasayan J. Chem. 2009 2 4 960 968
    [Google Scholar]
  17. Akbari Oryani M. Tarin M. Rahnama Araghi L. Synergistic cancer treatment using porphyrin-based metal-organic Frameworks for photodynamic and photothermal therapy. J. Drug Target. 2025 33 4 473 491 10.1080/1061186X.2024.2433551 39618308
    [Google Scholar]
  18. Kunjiappan S. Pavadai P. Vellaichamy S. Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review. Drug Dev. Res. 2021 82 3 309 340 10.1002/ddr.21758 33170541
    [Google Scholar]
  19. Radhakrishna G.K. Ammunje D.N. Kunjiappan S. A comprehensive review of capsaicin and its role in cancer prevention and treatment. Drug Res. 2024 74 5 195 207 10.1055/a‑2309‑5581 38729182
    [Google Scholar]
  20. Surya C. Lakshminarayana A.B.V. Ramesh S.H. Advancements in breast cancer therapy: The promise of copper nanoparticles. J. Trace Elem. Med. Biol. 2024 86 127526 10.1016/j.jtemb.2024.127526 39298835
    [Google Scholar]
  21. Theivendren P. Kunjiappan S. Pavadai P. Success stories: Impactful applications of cancer biomarkers. The Potential of Cancer Biomarkers. Amsterdam, Netherlands Elsevier 2025 297 331 10.1016/B978‑0‑443‑29279‑8.00015‑6
    [Google Scholar]
  22. Theivendren P. Pavadai P. Veerachamy S. Palanisamy P. Kunjiappan S. Surface receptor-targeted protein-based nanocarriers for drug delivery: Advances in cancer therapy. Nanotechnology 2025 36 12 122003 10.1088/1361‑6528/adad7a 39847811
    [Google Scholar]
  23. El-Tanani M. Nsairat H. Aljabali A.A. Matalka I.I. Alkilany A.M. Tambuwala M.M. Dual-loaded liposomal carriers to combat chemotherapeutic resistance in breast cancer. Expert Opin. Drug Deliv. 2024 21 2 309 324 10.1080/17425247.2024.2311812 38284386
    [Google Scholar]
  24. Kaur S. Alley S.C. Szapacs M. 2021 white paper on recent issues in bioanalysis: Mass spec of proteins, extracellular vesicles, CRISPR, chiral assays, oligos; nanomedicines bioanalysis; ICH M10 section 7.1; non-liquid & rare matrices; regulatory inputs (Part 1A – recommendations on endogenous compounds, small molecules, complex methods, regulated mass spec of large molecules, small molecule, PoC & Part 1B - regulatory agencies’ inputs on bioanalysis, biomarkers, immunogenicity, gene & cell therapy and vaccine). Bioanalysis 2022 14 9 505 580 10.4155/bio‑2022‑0078 35578993
    [Google Scholar]
  25. Vijayalakshmi M. Showbharnikhaa S. Snega K. Nadhiya J. Akshaya T. Translational research in drug discovery and development for sustainable healthcare. J Pharma Insights Res 2023 1 1 36 45
    [Google Scholar]
  26. Linney I.D. Kaila N. Inhibitors of immuno-oncology target HPK1–a patent review (2016 to 2020). Expert Opin. Ther. Pat. 2021 31 10 893 910 10.1080/13543776.2021.1924671
    [Google Scholar]
  27. Ivanenkov Y.A. Malyshev A.S. Terentiev V.A. Small molecule ATM inhibitors as potential cancer therapy: A patent review (2003–present). Expert Opin. Ther. Pat. 2025 35 2 111 136 10.1080/13543776.2024.2446228
    [Google Scholar]
  28. Nafie M.S. Fahmy S.A. Kahwash S.H. Diab M.K. Dawood K.M. Abbas A.A. Recent advances on anticancer activity of benzodiazine heterocycles through kinase inhibition. RSC Advances 2025 15 7 5597 5638 10.1039/D4RA08134J 39974315
    [Google Scholar]
  29. Wang X. Li J. Chen R. Li T. Chen M. Active ingredients from Chinese medicine for combination cancer therapy. Int. J. Biol. Sci. 2023 19 11 3499 3525 10.7150/ijbs.77720 37497002
    [Google Scholar]
  30. Saxena S. Mishra R. Mazumder A. Mazumder R. Shuaib M. An insight into the synthetic strategies and pharmacological effects of cinnoline derivatives. Indian J Pharm Educat Res 2025 59 1 13 29 10.5530/ijper.20253735
    [Google Scholar]
  31. Kirubakaran S. Kirubakaran S. Evolution of PIKK family kinase inhibitors A new age cancer therapeutics. Front. Biosci. 2020 25 8 1510 1537 10.2741/4866 32114443
    [Google Scholar]
  32. Tonk R.K. Bawa S. Kumar D. Therapeutic potential of cinnoline core: A comprehensive review. Mini Rev. Med. Chem. 2020 20 3 196 218 10.2174/1389557519666191011095858 31660825
    [Google Scholar]
  33. Yao W. Qiu H.M. Cheong K.L. Zhong S. Advances in anti-cancer effects and underlying mechanisms of marine algae polysaccharides. Int. J. Biol. Macromol. 2022 221 472 485 10.1016/j.ijbiomac.2022.09.055 36089081
    [Google Scholar]
  34. Verma S. Sahu B.D. Mugale M.N. Role of lncRNAs in hepatocellular carcinoma. Life Sci. 2023 325 121751 10.1016/j.lfs.2023.121751 37169145
    [Google Scholar]
  35. Mir M.A. Khan S.U. Aisha S. Cell cycle dysregulation in breast cancer. Therapeutic Potential Of Cell Cycle Kinases In Breast Cancer. Cham Springer 2023 103 131
    [Google Scholar]
  36. Gundarova J. Anticancer-effectiveness of herbal aldehyde derivatives on breast cancer cells. Thesis, Albert-Ludwigs-Universität Frei-burg 2024
    [Google Scholar]
  37. Huang J. Chen L. Wu J. Targeting the PI3K/AKT/mTOR signaling pathway in the treatment of human diseases: Current status, trends, and solutions. J. Med. Chem. 2022 65 24 16033 16061 10.1021/acs.jmedchem.2c01070 36503229
    [Google Scholar]
  38. Liu Y. Wang T. Wang W. Photopharmacology and photoresponsive drug delivery. Chem. Soc. Rev. 2025 54 12 5792 5835 10.1039/D5CS00125K 40309857
    [Google Scholar]
  39. Olayiwola Y. Gollahon L. Natural compounds and breast cancer: Chemo-preventive and therapeutic capabilities of chlorogenic acid and cinnamaldehyde. Pharmaceuticals 2024 17 3 361 10.3390/ph17030361 38543147
    [Google Scholar]
  40. Scott J.L. Enhancing the anticancer effects of Apiaceae spice phytochemicals. Thesis, University of Louisville 2024
    [Google Scholar]
  41. Sharma R. Mishra A. Bhardwaj M. Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics. J. Enzyme Inhib. Med. Chem. 2025 40 1 2489720 10.1080/14756366.2025.2489720 40256842
    [Google Scholar]
  42. Basu A. Lambring C.B. Akt isoforms: A family affair in breast cancer. Cancers 2021 13 14 3445 10.3390/cancers13143445 34298660
    [Google Scholar]
  43. Farghadani R. Naidu R. Curcumin: Modulator of key molecular signaling pathways in hormone-independent breast cancer. Cancers 2021 13 14 3427 10.3390/cancers13143427 34298639
    [Google Scholar]
  44. Al Khalily I. Megantara S. Aulifa D. Targeting molecular pathways in breast cancer using plant-derived bioactive compounds: A comprehensive review. J. Exp. Pharmacol. 2025 17 375 401 10.2147/JEP.S528132 40585862
    [Google Scholar]
  45. Panda V.K. Mishra B. Mahapatra S. Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review. Cancers 2025 17 2 234 10.3390/cancers17020234 39858015
    [Google Scholar]
  46. Singh D. Shukla G. The multifaceted anticancer potential of luteolin: Involvement of NF-κB, AMPK/mTOR, PI3K/Akt, MAPK, and Wnt/β-catenin pathways. Inflammopharmacology 2025 33 2 505 525 10.1007/s10787‑024‑01596‑8 39543054
    [Google Scholar]
  47. Adinew G.M. Taka E. Mochona B. Therapeutic potential of thymoquinone in triple-negative breast cancer prevention and progression through the modulation of the tumor microenvironment. Nutrients 2021 14 1 79 10.3390/nu14010079 35010954
    [Google Scholar]
  48. Dong C. Wang Y. Tu Z. Recent advances in ATM inhibitors as potential therapeutic agents. Future Med. Chem. 2022 14 23 1811 1830 10.4155/fmc‑2022‑0252 36484176
    [Google Scholar]
  49. Pal A.K. Sharma P. Zia A. Metabolomics and EMT markers of breast cancer: A crosstalk and future perspective. Pathophysiology 2022 29 2 200 222 10.3390/pathophysiology29020017 35736645
    [Google Scholar]
  50. Duan C. Yu M. Xu J. Li B.Y. Zhao Y. Kankala R.K. Overcoming cancer multi-drug resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed. Pharmacother. 2023 162 114643 10.1016/j.biopha.2023.114643 37031496
    [Google Scholar]
  51. Wdowiak P. Matysiak J. Kuszta P. Czarnek K. Niezabitowska E. Baj T. Quinazoline derivatives as potential therapeutic agents in urinary bladder cancer therapy. Front Chem. 2021 9 765552 10.3389/fchem.2021.765552 34805097
    [Google Scholar]
  52. Barathan M. Zulpa A.K. Ng S.L. Lokanathan Y. Ng M.H. Law J.X. Innovative strategies to Combat 5-fluorouracil resistance in colorectal cancer: The role of phytochemicals and extracellular vesicles. Int. J. Mol. Sci. 2024 25 13 7470 10.3390/ijms25137470 39000577
    [Google Scholar]
  53. Geraili A. Xing M. Mequanint K. Design and fabrication of drug‐delivery systems toward adjustable release profiles for personalized treatment. VIEW 2021 2 5 20200126 10.1002/VIW.20200126
    [Google Scholar]
  54. Martínez-Peña F. Pearson A.D. Tang E.L. Synthesis and biological evaluation of novel FiVe1 derivatives as potent and selective agents for the treatment of mesenchymal cancers. Eur. J. Med. Chem. 2022 242 114638 10.1016/j.ejmech.2022.114638 36001933
    [Google Scholar]
  55. Asif M. Almehmadi M.M. Alsaiari A.A. Aljuaid A. Allahyani M. Alsharif A. An overview of diverse biological activities of cinnoline scaffold. Mini Rev. Org. Chem. 2025 22 2 162 176 10.2174/0118756298265037231119063008
    [Google Scholar]
  56. Mylam Sreenivasan C. Theivendren P. Govindaraj S. Targeting TACE in breast cancer: Exploring the therapeutic potential of cinnoline derivatives through computational and experimental approaches. Essential Chem 2025 2 1 2536553 10.1080/28378083.2025.2536553
    [Google Scholar]
  57. Guo C. Yuan H. Wang Y. The interplay between PEGylated nanoparticles and blood immune system. Adv. Drug Deliv. Rev. 2023 200 115044 10.1016/j.addr.2023.115044 37541623
    [Google Scholar]
  58. Pandian S.R.K. Vijayakumar K.K. Murugesan S. Kunjiappan S. Liposomes: An emerging carrier for targeting Alzheimer’s and Parkinson’s diseases. Heliyon 2022 8 6 09575 10.1016/j.heliyon.2022.e09575 35706935
    [Google Scholar]
  59. Mazidi Z. Javanmardi S. Naghib S.M. Mohammadpour Z. Smart stimuli-responsive implantable drug delivery systems for programmed and on-demand cancer treatment: An overview on the emerging materials. Chem. Eng. J. 2022 433 134569 10.1016/j.cej.2022.134569
    [Google Scholar]
  60. Maboudi A.H. Lotfipour M.H. Rasouli M. Micelle-based nanoparticles with stimuli-responsive properties for drug delivery. Nanotechnol. Rev. 2024 13 1 20230218 10.1515/ntrev‑2023‑0218
    [Google Scholar]
  61. Goswami K.K. Banerjee S. Bose A. Baral R. Lactic acid in alternative polarization and function of macrophages in tumor microenvironment. Hum. Immunol. 2022 83 5 409 417 10.1016/j.humimm.2022.02.007 35300874
    [Google Scholar]
  62. Guo F. Du Y. Wang Y. Targeted drug delivery systems for matrix metalloproteinase-responsive anoparticles in tumor cells: A review. Int. J. Biol. Macromol. 2024 257 Pt 1 128658 10.1016/j.ijbiomac.2023.128658 38065446
    [Google Scholar]
  63. Omidi Y. Mobasher M. Castejon A.M. Mahmoudi M. Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. J. Drug Target. 2022 30 7 687 708 10.1080/1061186X.2022.2055045 35321601
    [Google Scholar]
  64. Liu Y. Sun X. Wei C. Targeted drug nanodelivery and immunotherapy for combating tumor resistance. Comb. Chem. High Throughput Screen. 2025 28 4 561 581 10.2174/0113862073296206240416060154 38676501
    [Google Scholar]
  65. Liu J. Chen C. Wang D. Zhang J. Zhang T. Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development. Eur. J. Med. Chem. 2021 217 113329 10.1016/j.ejmech.2021.113329 33740548
    [Google Scholar]
  66. Lian S. Du Z. Chen Q. From lab to clinic: The discovery and optimization journey of PI3K inhibitors. Eur. J. Med. Chem. 2024 277 116786 10.1016/j.ejmech.2024.116786 39180946
    [Google Scholar]
  67. Paul S. Pan S. Mukherjee A. De P. Nitric oxide releasing delivery platforms: Design, detection, biomedical applications, and future possibilities. Mol. Pharm. 2021 18 9 3181 3205 10.1021/acs.molpharmaceut.1c00486 34433264
    [Google Scholar]
  68. Ni Y. Huang R. Yang S. Pharmacokinetics and safety of oliceridine fumarate injection in chinese patients with chronic non-cancer pain: A phase i, single-ascending-dose, open-label clinical trial. Drug Des. Devel. Ther. 2024 2729 2743 10.2147/DDDT.S461416
    [Google Scholar]
  69. Gomha S.M. Abdelhady H.A. Hassain D.Z.H. Thiazole-based thiosemicarbazones: Synthesis, cytotoxicity evaluation and molecular docking study. Drug Des. Devel. Ther. 2021 15 659 677 10.2147/DDDT.S291579 33633443
    [Google Scholar]
  70. Saini P. Kumar K. Meena S. An overview of cinnolines, quinazolines and quinoxalines: Synthesis and pharmacological significance. N-Heterocycles: Synthesis and Biological Evaluation. Cham Springer Nature Singapore 2022 331 354 10.1007/978‑981‑19‑0832‑3_9
    [Google Scholar]
  71. Ong H.W. Adderley J. Tobin A.B. Drewry D.H. Doerig C. Parasite and host kinases as targets for antimalarials. Expert Opin. Ther. Targets 2023 27 2 151 169 10.1080/14728222.2023.2185511 36942408
    [Google Scholar]
/content/journals/cdth/10.2174/0115748855421240251126060327
Loading
Cinnoline Derivatives in Breast Cancer Therapy: A Comprehensive Review of Their Therapeutic Potential
Bentham Science Publishers ; https://doi.org/10.2174/0115748855421240251126060327
/content/journals/cdth/10.2174/0115748855421240251126060327
/content/journals/cdth/10.2174/0115748855421240251126060327
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: combination therapy ; cell cycle arrest ; cinnoline derivatives ; Breast cancer ; nanocarriers ; oncogenic pathways ; targeted drug delivery ; apoptosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test